Repros Therapeutics' IND for Proellex(R)-V Accepted By the FDA

THE WOODLANDS, Texas, Jan. 4, 2012 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc.® (Nasdaq:RPRX) today announced its Investigational New Drug Application (IND) for Proellex-V, or vaginally delivered Proellex, has been accepted by the FDA. The indication identified in the new IND is for the use of Proellex-V for the purpose of significant fibroid size reduction and symptom elimination with the goal of avoiding surgery. Approximately twenty percent of women of reproductive age in the U.S. have symptomatic fibroids with roughly 300,000 hysterectomies performed annually as a consequence. There is no approved chronic drug therapy for treatment of this debilitating condition.